James D Arecca Haemonetics Corp (HAE) insider trading activity

James D Arecca is EVP, Chief Financial Officer of HAEMONETICS CORP. Currently has a direct ownership of 28,292 shares of HAE, which is worth approximately $2.11 Million. The most recent transaction as insider was on May 30, 2025, when has been sold 5,864 shares (Common Stock) at a price of $69.38 per share, resulting in proceeds of $406,844. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.3K

63.1% 3M change

63.1% 12M change

Total Value Held $2.11 Million

James DArecca Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 30 2025	SELL Payment of exercise price or tax liability	$406,844 $69.38 p/Share	5,864 Reduced 17.17%	28,292 Common Stock
May 30 2025	BUY Grant, award, or other acquisition	-	12,221 Added 26.35%	34,156 Common Stock
May 16 2025	SELL Payment of exercise price or tax liability	$87,606 $70.31 p/Share	1,246 Reduced 7.75%	14,824 Common Stock
May 16 2025	BUY Grant, award, or other acquisition	-	7,111 Added 24.48%	21,935 Common Stock
May 15 2025	SELL Payment of exercise price or tax liability	$43,154 $69.38 p/Share	622 Reduced 3.73%	16,070 Common Stock
May 02 2025	SELL Payment of exercise price or tax liability	$41,757 $63.85 p/Share	654 Reduced 3.77%	16,692 Common Stock
May 17 2024	BUY Grant, award, or other acquisition	-	4,439 Added 20.38%	17,346 Common Stock
May 16 2024	SELL Payment of exercise price or tax liability	$33,274 $94.8 p/Share	351 Reduced 2.65%	12,907 Common Stock
May 15 2024	SELL Payment of exercise price or tax liability	$39,753 $96.49 p/Share	412 Reduced 3.01%	13,258 Common Stock
May 02 2024	SELL Payment of exercise price or tax liability	$40,318 $93.33 p/Share	432 Reduced 3.06%	13,670 Common Stock
May 16 2023	SELL Payment of exercise price or tax liability	$31,134 $89.21 p/Share	349 Reduced 2.42%	14,102 Common Stock
May 15 2023	BUY Grant, award, or other acquisition	-	4,205 Added 22.54%	14,451 Common Stock
May 02 2023	SELL Payment of exercise price or tax liability	$35,113 $81.66 p/Share	430 Reduced 4.03%	10,246 Common Stock
May 16 2022	BUY Grant, award, or other acquisition	-	4,774 Added 30.9%	10,676 Common Stock
May 02 2022	BUY Grant, award, or other acquisition	-	5,902 Added 50.0%	5,902 Common Stock

Also insider at

TXMD

TherapeuticsMD, Inc. Healthcare

Chief Financial Officer

PBH

Prestige Consumer Healthcare Inc. Healthcare

Director

James D Arecca

EVP, Chief Financial Officer

Boca Raton, FL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HAE shares.

Notify only if

Value

Insider Trading

Get notified when an Haemonetics Corp insider buys or sells HAE shares.

Notify only if

Operation

Value

Type

News

Receive news related to HAEMONETICS CORP

Track Activities on HAE

Account